FOLLICULAR LYMPHOMA GRADE 3
Clinical trials for FOLLICULAR LYMPHOMA GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR LYMPHOMA GRADE 3 trials appear
Sign up with your email to follow new studies for FOLLICULAR LYMPHOMA GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests an experimental drug called XNW5004 in 65 people with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding to at least three prior treatments. Participants take the drug twice daily for 28-day cycles. The main goal is to see h…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3
Phase: PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: FOLLICULAR LYMPHOMA GRADE 3
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC